Business Context and Reporting Period
This Form 8-K was filed by Talphera, Inc. (formerly AcelRx Pharmaceuticals, Inc.) on January 9, 2024. The report details a corporate name change and the corresponding update to its stock trading symbol on the Nasdaq Global Market.
Key Financial Metrics
This filing is a current report regarding corporate governance and branding changes. It does not provide financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics.
Material Changes
- Corporate Name: Changed from "AcelRx Pharmaceuticals, Inc." to "Talphera, Inc."
- Trading Symbol: Changed to TLPH, effective at market open on January 10, 2024.
- CUSIP Number: Remains unchanged at 00444T209.
- Governance Documents: Filed a Certificate of Amendment to the Certificate of Incorporation and amended Bylaws to reflect the new name.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. The primary disclosure is the execution of the name and symbol change.
Investor Verification Checklist
- Verify the new ticker symbol TLPH is active on the Nasdaq Global Market starting January 10, 2024.
- Confirm that existing holdings under the old name (AcelRx) automatically transition to the new name without action required by the shareholder.
- Review the attached press release (Exhibit 99.1) for any strategic rationale behind the rebranding not detailed in the 8-K text.